Cyclerion Therapeutics
CYCN
15 hedge funds and large institutions have $3.58M invested in Cyclerion Therapeutics in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 2 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.86% less ownership
Funds ownership: 44.52% → 43.65% (-0.86%)
2% less capital invested
Capital invested by funds: $3.66M → $3.58M (-$77.6K)
12% less funds holding
Funds holding: 17 → 15 (-2)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tyndall Capital Partners
New York
|
+$48.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.64K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.47K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$49.3K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.91K |
| 4 |
BlackRock
New York
|
-$2.4K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.68K |
CYCN Hedge Fund Activity: Q4 2023 in Review
15 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q4 2023, worth a combined $3.58M — down 2.1% from $3.66M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CYCN and 0 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Tyndall Capital Partners, adding an estimated $48.3K. The largest seller was Vanguard Group, cutting an estimated $49.3K.
- 15 institutional investors held Cyclerion Therapeutics (CYCN) as of Q4 2023, down from 17 in Q3 2023.
- Funds reported $3.58M of Cyclerion Therapeutics stock for Q4 2023, down 2.1% quarter-over-quarter.
- 0 funds opened new Cyclerion Therapeutics positions in Q4 2023 and 2 closed out, a net change of -2 holders.
- The largest Cyclerion Therapeutics buyer in Q4 2023 was Tyndall Capital Partners, an estimated $48.3K added.
- The largest Cyclerion Therapeutics seller in Q4 2023 was Vanguard Group, an estimated $49.3K sold.
Based on aggregated 13F filings for Q4 2023.